Purple Biotech Ltd. (PPBT) stock
PPBTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.63+0.07 (+4.49%)
Close on Nov 13, 2026Market cap $1.52MP/E 0.0Yield –
Purple Biotech r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $3.73M, down 51.0% from the year before. Over ten years it grew 3.8% a year on average. The highest annual figure on record is $17.03M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.73M | -51.0% |
| FY2024 | Dec 31, 2024 | $7.62M | -55.3% |
| FY2023 | Dec 31, 2023 | $17.03M | +4.4% |
| FY2022 | Dec 31, 2022 | $16.32M | +38.0% |
| FY2021 | Dec 31, 2021 | $11.83M | +63.4% |
| FY2020 | Dec 31, 2020 | $7.24M | +217.7% |
| FY2019 | Dec 31, 2019 | $2.28M | -56.8% |
| FY2018 | Dec 31, 2018 | $5.27M | +13.5% |
| FY2017 | Dec 31, 2017 | $4.64M | +11.0% |
| FY2016 | Dec 31, 2016 | $4.18M | +63.3% |
| FY2015 | Dec 31, 2015 | $2.56M | – |
See a number that looks wrong?